Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the USA on 26th November 2019. The patent number is 10,488,530.
Related Posts
George Sutherland appointed TRUEinvivo Ltd.'s first Chairman, bringing extensive experience in medical devices and corporate finance.
TrueInvivo enhances cancer care with accurate, high-resolution in-vivo dosimetry system, optimizing radiotherapy outcomes.
TRUEinvivo's 2018 achievements include prototype development, patent filings, fundraising, multiple awards, and market expansion, setting the stage for a busy 2019.
TRUEinvivo named finalist in Surrey Business Awards for Business Innovation of the Year, recognizing DOSEmapper™ technology
